Head to Head Contrast: Longevity Health (NASDAQ:XAGE) & Biosig Technologies (NASDAQ:STEX)

Longevity Health (NASDAQ:XAGE) and Biosig Technologies (NASDAQ:STEX) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Longevity Health and Biosig Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0	0	0	0	0.00
Biosig Technologies	1	0	0	0	1.00

Institutional & Insider Ownership

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by company insiders. Comparatively, 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Longevity Health and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Biosig Technologies	N/A	N/A	-64.96%

Volatility and Risk

Longevity Health has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Earnings & Valuation

This table compares Longevity Health and Biosig Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05 million	0.49	-$10.37 million	($3.91)	-0.07
Biosig Technologies	$40,000.00	5,087.82	-$10.33 million	($1.35)	-0.84

Biosig Technologies has lower revenue, but higher earnings than Longevity Health. Biosig Technologies is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Summary

Biosig Technologies beats Longevity Health on 8 of the 11 factors compared between the two stocks.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.